Informations générales (source: ClinicalTrials.gov)
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-low Europe)
Observational
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (Voir sur ClinicalTrials)
octobre 2023
septembre 2028
02 décembre 2025
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult
patients with unresectable or metastatic HER2-low breast cancer who have received prior
chemotherapy in the metastatic setting or developed disease recurrence during or within 6
months of completing adjuvant chemotherapy.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:23 | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 10/04/2025 13:12:05 | Contact (sur clinicalTrials) | |||
| HOPITAL FOCH | Asmahane BENMAZIANE TEILLET | 01/12/2025 08:26:44 | Contacter | ||
| AP-HP Assistance publique - Hôpitaux de Paris | 07/03/2025 14:58:34 | Contacter | |||
| AP-HP - Hôpital Henri Mondor-Albert Chenevier | |||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospitalier de Sens - 89108 - Sens Cédex - France | Principal Investigator | Contact (sur clinicalTrials) | |||
| CHU Martinique - 97261 - Fort De France Cedex - France | Principal Investigator | Contact (sur clinicalTrials) | |||
Critères
Tous
- Adult patient (age ≥ 18 years) with histological or cytological confirmed diagnosis
of unresectable and/or mBC
- Documented HER2-low status (IHC1+, IHC2+/ISH-)
- Patients who have received prior chemotherapy in the metastatic setting or patients
who have developed disease recurrence during or within 6 months of completing
adjuvant chemotherapy
- Decision to newly initiate therapy of T-DXd or conventional chemotherapy according
to the physicians choice per SmPC
- Written and signed Informed Consent to participate in the study
Exclusion Criteria:
- Pregnancy or breastfeeding
- Patients who at time of data collection for this study are participating in or have
participated in an interventional study that remains blinded.
No other specific exclusion criteria are defined, as patients will be treated according
to the proposed indication statements in the SmPC.